Replimune (NASDAQ:REPL) experienced a dramatic surge in its stock price on Friday, jumping approximately 131% to near $12.50 in premarket trading. The rally followed a pivotal decision by a panel of U.S. Food and Drug Administration (FDA) advisers, who voted 10-3 in favor of the efficacy data from the company's IGNYTE trial for RP1, a novel oncolytic immunotherapy. The panel's positive recommendation countered earlier regulatory concerns raised by FDA staff earlier in the week, which had cast doubt on the study's design and the way responses were measured.
The market's response was swift and substantial. Based on an estimated 84.03 million shares outstanding, the surge added approximately $595.8 million to Replimune's basic equity value, lifting it from $454.6 million at Thursday's close to $1.05 billion in premarket trading. The enterprise value also climbed by the same amount, reaching $864.8 million, after adjusting for cash and debt. These figures, however, do not account for potential dilution from warrants or future capital raises.
The FDA's final decision is expected on Sunday, August 2, and while advisory panel votes are not binding, they often carry significant weight. Analysts have weighed in, with BMO Financial Group's Evan Seigerman describing the panel testimony as having made a compelling case for RP1 despite FDA criticism, and suggesting that accelerated approval is now almost certain. Wedbush has raised its price target to $12, though that remains slightly below the current premarket level.
The efficacy results from the IGNYTE trial are notable when compared to an already approved treatment for the same indication. RP1, when combined with Opdivo (nivolumab) from Bristol Myers Squibb (NYSE:BMY), demonstrated an objective response rate of 33.6% in 140 patients, with a median response duration of 24.8 months. This compares favorably to Amtagvi, Iovance Biotherapeutics' (NASDAQ:IOVA) cell therapy, which showed a 31.5% response rate in 73 patients and had not yet reached a median response duration at the time of approval. However, the delivery methods differ significantly: RP1 is administered via tumor injection along with nivolumab, while Amtagvi requires tumor removal, product creation, hospital conditioning, and IL-2 therapy, and was associated with a 7.5% treatment-related death rate among regimen starters.
Experts have noted the practical advantages of RP1. Melanoma specialist Hussein Tawbi described it as "a lot safer, a lot easier" compared to Amtagvi, a sentiment that resonated with the panel during discussions. However, FDA reviewers remained unconvinced about the efficacy claims, pointing out that response criteria may have artificially inflated the results and that the added benefit of RP1 over nivolumab alone was not demonstrated. The trial, which lacked a control arm, made the median overall survival of 32.9 months difficult to interpret, leaving significant uncertainty.
Replimune's ongoing randomized IGNYTE-3 study is expected to provide overall survival data in 2030, meaning that any accelerated approval would come well before those results are available. This timeline introduces a key risk: if the confirmatory trial fails, the approval could be withdrawn.
Beyond the regulatory hurdle, Replimune faces significant financial pressures. The company's cash burn has accelerated, with operating cash use increasing 46% to $280.3 million in fiscal 2026, while net loss widened to $313.9 million. Cash and short-term investments fell 44% to $268.9 million as of March 31, which the company says supports operations into early 2027 without factoring in potential product revenue. The company also has 14.1 million pre-funded warrants outstanding, which at Friday's premarket price would be worth approximately $176 million, adding to potential dilution concerns.
CEO Sushil Patel expressed optimism, stating, "We look forward to continuing to work with the FDA." Investors are now bracing for the regulator's decision, which remains a binary outcome. The FDA could still deny approval despite the positive panel vote, or grant it with stringent post-marketing obligations. Even with approval, the high cash outflow, potential dilution, or failure in confirmatory studies could erase much of Friday's gains. The immediate risk is clear: the stock's future hinges on the FDA's ruling and the company's ability to manage its financial runway.
